Stryker Q4 sales $4.7B (+10.3%), FY21 adj. EPS $9.09 (+22.3%); forecasts FY22 adj. EPS $9.60-10.00

STRYKER CORP

2021-FY EPS reported $5.21 revenue$17,108,000,000

Q4 net sales $4.7B, +10.3% YoY; organic +9.0% vs 2020, +6.2% vs 2019.
Q4 reported EPS $1.73 (+16.1%); adjusted EPS $2.71 (-3.6%) year-over-year.
Full-year net sales $17.1B, +19.2% YoY; reported EPS $5.21 (+24.0%); adjusted EPS $9.09 (+22.3%).
MedSurg & Neurotech FY organic sales +13.1%; Orthopaedics & Spine FY organic +12.0%.
2022 outlook: organic sales growth 6%-8%; adjusted EPS $9.60-$10.00; expects ~1% price headwind.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.